Buy & Sell Nokia Corp (NOK) – Nokia Corp Price Today
Aura AI Summary
Key Stats
- $75.37BMarket Cap
- TechnologySector
- -7.98%3M Drawdown
- $72.11BEnterprise Value
- 1.2%Dividend Yield
- 56% Buy | 44% SellTrading Activity
- 66 daysTypical Hold Time
Nokia Corp (NOK) is currently valued at a market capitalization of $75.37B, with an enterprise value of $72.11B. Over the past 52 weeks, Nokia Corp has traded between a low of $4.05 and a high of $14.71, highlighting its annual price range. Over the past three months, Nokia Corp has recorded a drawdown of -7.98%, reflecting recent price volatility. Nokia Corp offers a dividend yield of 1.2%, with the most recent dividend of $0.05 paid on 28 Apr 26. On average, investors hold Nokia Corp for approximately 66 days, indicating typical investor behavior on the platform.
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Most Recent News
BC launches Outdoor Sector Coalition to boost economy, health, and conservation of its outdoors.
A coalition of over 2,000 organizations in British Columbia has formed to support the province's outdoor sector, which is a $17 billion industry employing 80,000 people. The coalition aims to enhance health benefits, support outdoor businesses, and p...

Nvidia's Q1 2027 earnings face high expectations amid strong past beats but mixed stock reactions.
Nvidia is set to report its Q1 2027 earnings with Wall Street expecting $78.8 billion in revenue and $1.77 EPS, marking record growth. Historically, Nvidia has consistently beaten revenue and EPS estimates, but recent earnings have shown that the sto...

ESR1-mutated metastatic breast cancer market to grow 9.6% CAGR with new oral SERDs and targeted therapies.
The ESR1-mutated metastatic breast cancer market is projected to grow rapidly at a 9.6% CAGR from 2026 to 2036, driven by rising cases of endocrine-resistant HR-positive/HER2-negative breast cancer and advances in precision oncology. Novel therapies ...
